drugset / Trial / NCT04229030
RZL-012 for Dercum's Disease Lipomas
RandomizedParallel-groupDouble-blindTreatment
Summary
Thirty-eight (38) subjects will be included in the study. Subjects will be randomized in a ration of 1:1 to be treated with RZL-012 or placebo. Subjects will be injected with a different doses of RZL-012 according to their lipomas sizes. The total of 38 subjects will be enrolled in 3 clinical sites.
Timeline
- Start
- 2020-07-30
- Primary completion
- 2021-02-20
- Completion
- 2021-02-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | UTENPANIUM | Small molecule | 5 mg | Subcutaneous |
| Comparator | UTENPANIUM | Small molecule | 20 mg | Subcutaneous |
| Comparator | UTENPANIUM | Small molecule | 80 mg | Subcutaneous |
| Comparator | UTENPANIUM | Small molecule | 100 mg | Subcutaneous |
| Comparator | UTENPANIUM | Small molecule | 120 mg | Subcutaneous |